Critical appraisal and pooled analysis of telmisartan alone or in combination with hydrochlorothiazide for achieving blood pressure goals

References

• OgiharaTKikuchiKMatsuokaHJapanese Society of Hypertension Committee. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009)Hypertens Res2009324107
   Web of Science ®Google Scholar
• ObaraTOhkuboTFunabashiJIsolated uncontrolled hypertension at home and in the office among treated hypertensive patients from the J-HOME studyJ Hypertens2005231653166016093909
   PubMed Web of Science ®Google Scholar
• ItohSSynergic effect mechanisms on ARB/diuretic combination tabletsJ Blood Press20061313041307
   Google Scholar
• SiragyHMBedigianMMechanism of action of angiotensin-receptor blocking agentCurr Hypertens Rep1999128929510981080
   PubMedGoogle Scholar
• SiragyHMAT (1) and AT (2) receptors in the kidney: role in disease and treatmentAm J Kidney Dis2000363 Suppl 1S4S910986153
   PubMed Web of Science ®Google Scholar
• WeirMRDzauVJThe renin-angiotensin-aldosterone system: a specific target for hypertension managementAm J Hypertens199912S205S213
   PubMed Web of Science ®Google Scholar
• SchiffrinELVascular and cardiac benefits of angiotensin receptor blockersAm J Med200211340941812401536
   PubMed Web of Science ®Google Scholar
• SchmiederREMechanisms for the clinical benefits of angiotensin II receptor blockersAm J Hypertens20051872073015882557
   PubMed Web of Science ®Google Scholar
• MorimotoSYanoYMakiKSawadaKRenal and vascular protective effects of telmisartan in patients with essential hypertensionHypertens Res20062956757217137211
   PubMed Web of Science ®Google Scholar
• WienenWEntzerothMvan MeelJCA review on telmisartan: a novel, long-acting angiotensin II-receptor antagonistCardiovasc Drug Rev200018127156
   Google Scholar
• SharpeMJarvisBGoaKLTelmisartan: a review of its use in hypertensionDrugs2001611501152911558835
   PubMed Web of Science ®Google Scholar
• LacourcièreYKrzesinskiJMWhiteWBDavidaiGSchumacherHSustained antihypertensive activity of telmisartan compared with valsartanBlood Press Monit2004920321015311147
   PubMed Web of Science ®Google Scholar
• BensonSCPershadsinghHAHoCIIdentification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activityHypertension20043993100215007034
   PubMed Web of Science ®Google Scholar
• SchuppMJankeJClasenRAngiotensin type I receptor blockers induce peroxisome proliferators-activated receptor-gamma activityCirculation20041092054205715117841
   PubMed Web of Science ®Google Scholar
• JankeJSchuppMEngeliSAngiotensin type 1 receptor antagonists induce human in vitro adipogenesis through peroxisome proliferators-activated receptor-γ activationJ Hypertens2006241809181616915030
   PubMed Web of Science ®Google Scholar
• ErbeDVGartrellKZhangYLMolecular activation of PPAR-γ by angiotensin II type 1-receptor antagonistsVasc Pharmaco200645154162
   PubMed Web of Science ®Google Scholar
• PerhadsinghHAPeroxisome proliferator-activated receptor-γ therapeutic target of diseases beyond diabetes: quo vadisExpert Opin Invest Drugs200413215228
   Web of Science ®Google Scholar
• SavageDBTanGDAceriniCLHuman metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-γDiabetes20035291091712663460
   PubMed Web of Science ®Google Scholar
• SchuppMClemenzMGinesteRMolecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activityDiabetes2005543442345216306360
   PubMed Web of Science ®Google Scholar
• MiuraYYamamotoNTsunekawaSReplacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetesDiabetes Care20052875775815735228
   PubMed Web of Science ®Google Scholar
• YamauchiTKamonJWakiYThe fat-derived hormone adiponectin reverses insulin resistance associated with both lipotrophy and obesityNat Med794194611479627
   PubMed Web of Science ®Google Scholar
• RossRAtherosclerosis: An inflammatory diseaseN Engl J Med19993401151269887164
   PubMed Web of Science ®Google Scholar
• The SOLVD InvestigatorsEffect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failureN Engl J Med19913252933022057034
   PubMed Web of Science ®Google Scholar
• PfefferMABraunwaldEMoyéLAEffect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the survival and ventricular enlargement trialN Engl J Med19923276696771386652
   PubMed Web of Science ®Google Scholar
• Heart Outcomes Prevention Evaluation Study InvestigatorsEffects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE sub-studyLancet2000355253259 [Erratum, Lancet. 2000;356:860.]10675071
   PubMed Web of Science ®Google Scholar
• Blood Pressure Lowering Treatment Trialists’ CollaborationBlood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin systemJ Hypertens20072595195817414657
   PubMed Web of Science ®Google Scholar
• The ONTARGET InvestigatorsTelmisartan, ramipril, or both in patients at high risk for vascular eventsN Engl J Med20083581547155918378520
   PubMed Web of Science ®Google Scholar
• The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) InvestigatorsEffects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trialLancet200937211741183
   Web of Science ®Google Scholar
• LindholmLHIbsenHDahlofBCardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenololLancet2002359995100311937178
   PubMed Web of Science ®Google Scholar
• JuliusSKjeldsenSEWeberMOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trialLancet20043632022203115207952
   PubMed Web of Science ®Google Scholar
• GrangerCBMcMurrayJVYusufSEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trialLancet200336277277613678870
   PubMed Web of Science ®Google Scholar
• HigakiJThe examination of telmisartan 40 mg/hydrochlorothiazide for patients with essential hypertensionJ New Remedies and Clinic200857308325
   Google Scholar
• LacourcièreYTytusRO’KeefeDLenisJOrchardRMartinKEfficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapyJ Hum Hypertens20011576377011687919
   PubMed Web of Science ®Google Scholar
• StamlerJRoseGStamlerRElliottPDyerAMarmotMINTERSALT study findings. Public health and medical care implicationHypertension1989145705772807518
   PubMed Web of Science ®Google Scholar
• McGillJBReillyPATelmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: A multicenter, randomized, double-blind, placebo-controlled, parallel-group trialClin Ther20012383385011440284
   PubMed Web of Science ®Google Scholar
• Internal document for Nippon Boehringer Ingelheim (data submitted to the Japanese Ministry of Health and Labor for the approval of telmisartan/HCTZ combination tablets).
   Google Scholar
• HigakiJThe examination of long-term usage of telmisartan 40 mg/hydrochlorothiazide tablet and telmisartan 80 mg/hydrochlorothiazide tablet for patients with essential hypertensionJ New Remedies and Clinic200958346361
   Google Scholar
• NeutelJMLittlejohnTWChrysantSGSinghATelmisartan Study GroupTelmisartan/hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertensionHypertens Res20052855556316335883
   PubMed Web of Science ®Google Scholar
• SharmaAMDavidsonJKovalSLacourcièreYTelmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: The SMOOTH studyCardiovasc Diabetol200762817910747
   PubMed Web of Science ®Google Scholar